{"id":"eloctate","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Factor VIII inhibition","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Device-related thrombosis","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Rash papular","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Arthralgia","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Malaise","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Myalgia","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"0.5%","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"0.4%","severity":"common","organSystem":""},{"effect":"Dysgeusia","drugRate":"0.4%","severity":"common","organSystem":""},{"effect":"Bradycardia","drugRate":"0.4%","severity":"common","organSystem":""},{"effect":"Hypertension","drugRate":"0.4%","severity":"common","organSystem":""},{"effect":"Hot flush","drugRate":"0.4%","severity":"common","organSystem":""},{"effect":"Angiopathy","drugRate":"0.4%","severity":"common","organSystem":""},{"effect":"Cough","drugRate":"0.4%","severity":"common","organSystem":""},{"effect":"Lower abdominal pain","drugRate":"0.4%","severity":"common","organSystem":""},{"effect":"Back pain","drugRate":"0.4%","severity":"common","organSystem":""},{"effect":"Joint swelling","drugRate":"0.4%","severity":"common","organSystem":""},{"effect":"Chest pain","drugRate":"0.4%","severity":"common","organSystem":""},{"effect":"Feeling cold","drugRate":"0.4%","severity":"common","organSystem":""}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Myocardial infarction","drugRate":"0.7%","severity":"serious"},{"effect":"Procedural hypotension","drugRate":"0.4%","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":["ELOCTATE- antihemophilic factor (recombinant), fc fusion protein"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"e1419c33-ef07-4268-be1f-c8993502d597","title":"ELOCTATE (ANTIHEMOPHILIC FACTOR (RECOMBINANT), FC FUSION PROTEIN) KIT [BIOVERATIV THERAPEUTICS INC.]"},"ecosystem":[],"mechanism":{},"_scrapedAt":"2026-03-27T23:45:19.739Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Efmoroctocog_alfa","title":"Efmoroctocog alfa","extract":"Efmoroctocog alfa, sold under the brand name Elocta among others, is a medication for the treatment and prophylaxis of bleeding in people with hemophilia A. Efmoroctocog alfa is a recombinant human coagulation factor VIII, Fc fusion protein (rFVIIIFc). It is produced by recombinant DNA technology in a human embryonic kidney (HEK) cell line."},"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Hereditary factor VIII deficiency disease","diseaseId":"hereditary-factor-viii-deficiency-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04293523","phase":"","title":"A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2020-03-30","conditions":"Hemophilia A","enrollment":427},{"nctId":"NCT04690322","phase":"PHASE4","title":"POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2021-04-15","conditions":"Hemophilia A, Factor VIII","enrollment":28},{"nctId":"NCT05856266","phase":"PHASE4","title":"An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog Alfa","status":"TERMINATED","sponsor":"Swedish Orphan Biovitrum","startDate":"2023-08-24","conditions":"Hemophilia A, Hemophilia B","enrollment":10},{"nctId":"NCT02976753","phase":"","title":"Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2016-12","conditions":"Hemophilia A","enrollment":361},{"nctId":"NCT03055611","phase":"","title":"A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2017-05-09","conditions":"Haemophilia A, Haemophilia B","enrollment":201},{"nctId":"NCT03103542","phase":"PHASE4","title":"Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2017-08-29","conditions":"Hemophilia A","enrollment":16},{"nctId":"NCT04728217","phase":"PHASE4","title":"Health Related Quality of Life of Youth and Young Adults With Haemophilia A","status":"COMPLETED","sponsor":"The League of Clinical Research, Russia","startDate":"2021-04-15","conditions":"Hemophilia A","enrollment":30},{"nctId":"NCT04303559","phase":"PHASE3","title":"The Hemophilia Inhibitor Prevention Trial","status":"TERMINATED","sponsor":"Margaret Ragni","startDate":"2021-10-11","conditions":"Hemophilia A Without Inhibitor","enrollment":1},{"nctId":"NCT04303572","phase":"PHASE3","title":"The Hemophilia Inhibitor Eradication Trial","status":"TERMINATED","sponsor":"Margaret Ragni","startDate":"2021-11-01","conditions":"Hemophilia A With Inhibitor","enrollment":1},{"nctId":"NCT02234323","phase":"PHASE3","title":"An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A","status":"COMPLETED","sponsor":"Bioverativ, a Sanofi company","startDate":"2015-01-12","conditions":"Hemophilia A","enrollment":108},{"nctId":"NCT03093480","phase":"PHASE4","title":"A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)","status":"COMPLETED","sponsor":"Bioverativ, a Sanofi company","startDate":"2017-12-08","conditions":"Hemophilia A With Inhibitors","enrollment":16},{"nctId":"NCT02546622","phase":"","title":"ATHN 2: Factor Switching Study","status":"COMPLETED","sponsor":"American Thrombosis and Hemostasis Network","startDate":"2015-09","conditions":"Hemophilia","enrollment":310},{"nctId":"NCT02083965","phase":"PHASE1","title":"Pharmacokinetics of rFVIIIFc at Two Vial Strengths","status":"COMPLETED","sponsor":"Bioverativ Therapeutics Inc.","startDate":"2014-03","conditions":"Severe Hemophilia A","enrollment":19},{"nctId":"NCT01458106","phase":"PHASE3","title":"Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A","status":"COMPLETED","sponsor":"Bioverativ Therapeutics Inc.","startDate":"2012-11","conditions":"Hemophilia A","enrollment":71},{"nctId":"NCT02502149","phase":"PHASE3","title":"Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale","status":"COMPLETED","sponsor":"Bioverativ Therapeutics Inc.","startDate":"2015-08","conditions":"Severe Hemophilia A","enrollment":24},{"nctId":"NCT01454739","phase":"PHASE3","title":"Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A","status":"COMPLETED","sponsor":"Bioverativ Therapeutics Inc.","startDate":"2011-12","conditions":"Hemophilia A","enrollment":240},{"nctId":"NCT02392156","phase":"","title":"Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes","status":"TERMINATED","sponsor":"Bioverativ Therapeutics Inc.","startDate":"2015-07","conditions":"Hemophilia A, Hemophilia B","enrollment":3},{"nctId":"NCT02586012","phase":"PHASE2","title":"Weight-based Dosing in Hemophilia A","status":"TERMINATED","sponsor":"Craig Seaman","startDate":"2015-09","conditions":"Hemophilia","enrollment":30},{"nctId":"NCT03272568","phase":"EARLY_PHASE1","title":"Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-02-14","conditions":"Hemophilia, Menstrual Flow Excessive","enrollment":3},{"nctId":"NCT02196207","phase":"PHASE3","title":"Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform","status":"WITHDRAWN","sponsor":"Margaret Ragni","startDate":"2020-08","conditions":"Severe Hemophilia A","enrollment":""},{"nctId":"NCT03248141","phase":"","title":"Understanding Hemophilia A and B Drug Dosage Administration Patterns","status":"TERMINATED","sponsor":"Pfizer","startDate":"2017-09-01","conditions":"Hemophilia A, Hemophilia B","enrollment":11},{"nctId":"NCT03405337","phase":"","title":"Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-02-14","conditions":"Hemophilia A","enrollment":160}],"_emaApprovals":[],"_faersSignals":[{"count":1353,"reaction":"HAEMORRHAGE"},{"count":282,"reaction":"HAEMARTHROSIS"},{"count":219,"reaction":"FALL"},{"count":217,"reaction":"ARTHRALGIA"},{"count":185,"reaction":"LIMB INJURY"},{"count":183,"reaction":"TRAUMATIC HAEMORRHAGE"},{"count":162,"reaction":"JOINT INJURY"},{"count":154,"reaction":"CONTUSION"},{"count":151,"reaction":"SPONTANEOUS HAEMORRHAGE"},{"count":115,"reaction":"HEAD INJURY"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":28,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Eloctate","genericName":"Eloctate","companyName":"University of Texas Southwestern Medical Center","companyId":"university-of-texas-southwestern-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}